Searched for
TEVA NATCO PHARMA
Natco Pharma launches additional strengths of generic version of Revlimid in USNatco Pharma Ltd on Friday said it has launched additional strengths for its generic lenalidomide capsules used in the treatment of multipl...- Buy Natco Pharma, target price Rs 1021: ICICI SecuritiesNatco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 15529.31 Crore) operating in Pharmaceutic...
- US Court rules in favour of Mylan for Copaxone patents: NatcoIn December 2016, the US Patent and Trademark Office (PTO) had ruled in favour of Mylan and three patents related to Copaxone 40 mg/mL were...
- US court finds Teva's Copaxone patent invalid again: Natco PharmaNatco Pharma, a city-based drug maker, today said the US Court of Appeals for Federal Court has again found one of the patents of Teva's Co...
- Natco Pharma ends 5% higher as US Supreme Court invalidates rival Teva's patent for CopaxoneCopaxone (Glatiramer Acetate) is used in the treatment of relapsing-remitting multiple sclerosis.
- Setback to Natco pharma; US Supreme Court sends Teva patent case to Federal CircuitThe US Supreme Court has sent back the patent case related to Teva's multiple sclerosis drug Copaxone for a review by the Federal Circuit.
- Natco slumps; US court rules for Teva in drug patent caseUS Supreme Court sends patent case back to lower court. Generic launches by Natco and other pharma companies will be delayed, say analysts.
- Natco Pharma's partner Mylan Inc files ANDA for generic CopaxoneAccording to IMS health, Copaxone 40 mg/mL had US sales of nearly USD 411.5 million for the 12 months ending June 30, 2014, it added.
- Natco Pharma shares climb 7.5 per cent on boursesNatco's stock surged 7.50 per cent to settle at Rs 769.35 on the BSE. In intra-day trade, it soared 12.92 per cent to Rs 808.15.
- US Patents rejects Teva's plea on Copaxone; Natco shares upHyderabad-based Natco markets Copaxone (Glatiramer Acetate) -- used in the treatment of relapsing-remitting multiple sclerosis -- in the US...
- Natco Pharma shares up 5 pc after Teva's Copaxone plea is rejectedShares of Natco gained after US Patent and Trademark Office rejected Teva Pharma's application seeking a re-issue of a patent to its drug C...
- Natco set for US launch of generic copy of Teva’s drugIf the Hyderabad-based company begins selling the drug now, it may face penal damages on losing the patent battle with Teva.
- Natco Pharma cracks 19% as US justices agrees to hear Teva's Copaxone appealThe decision by the Supreme Court comes at a time when Teva is switching its daily version of Copaxone to twice a week version.
- Natco Pharma rallies over 8% as US Court rejects stay request on CopaxoneShares of Natco Pharma surged higher after the US Supreme Court rejected rival Teva Pharma’s request for stay on Copaxone drug.
- Natco Pharma gets favourable ruling for generic Copaxone in USNatco Pharma on Saturday said it has obtained a favourable ruling from a US Court that paves way for launch of generic Copaxone.
- Natco loses US patent suit by Israeli pharma major TevaIndia's Natco Pharma has lost a patent infringement suit in the US filed by Israeli pharma major Teva over sale of Copaxone, a drug used to...
- Natco, Mylan to appeal against New York district court verdictThe decision by the US court covers several patents for the chemical composition of Copaxone, methods of using the product and processes fo...
- Natco Pharma loses patent case against Teva Pharmaceutical Industries of anti-sclerosis drugNatco Pharma has lost a patent litigation against Israel's Teva Pharmaceutical Industries in the US over multiple sclerosis treatment drug,...
- Natco Pharma plunges after NY court verdictShares of Natco Pharma are witnessing selling pressure after a New York court ruled in favour of Teva in a patent case against the company.
- Natco inks agreement with Mylan for CopaxoneHome grown major Natco Pharma today said it has signed a licence and supply agreement with US-based Mylan for the global sale of generic ve...
Load More
